martes, 2 de junio de 2026
Food Addiction Debate: Symptoms, Causes, and Treatment
https://www.news-medical.net/health/Food-Addiction-Debate-Symptoms-Causes-and-Treatment.aspx
Food addiction describes addiction-like responses to ultra-processed foods, but it is not yet a formal DSM-5 or ICD-11 diagnosis. Evidence links it to cravings, loss of control, reward pathways, trauma, and eating-disorder overlap.
As the prevalence of obesity continues to rise throughout the world, emerging research indicates that a subset of individuals may experience addiction-like responses to ultra-processed foods (UPFs), with symptoms similar to those observed in substance use disorders (SUDs). However, food addiction is not currently a formal diagnosis in the DSM-5 or ICD-11, and its validity remains debated.3,5 In this context, food is considered a substance, with food addiction symptoms most commonly associated with foods high in fats and/or refined carbohydrates like sugar.
AI is mapping health stigma faster than it is fixing it
https://www.news-medical.net/news/20260601/AI-is-mapping-health-stigma-faster-than-it-is-fixing-it.aspx
A new review shows that AI can expose stigmatizing language at scale, but the evidence that it can safely reduce stigma in real-world healthcare remains thin.
In a recent study published in the journal npj Digital Medicine, researchers explored the role of artificial intelligence (AI) in health-related stigma.
Closer to the edge The Lancet Planetary Health
Closer to the edge
The Lancet Planetary Health
https://www.thelancet.com/journals/lanplh/article/PIIS2542-5196(26)00053-7/fulltext?dgcid=raven_jbs_etoc_email
The burden of El Niño–Southern Oscillation-related dengue attributable to anthropogenic climate change: a multicountry modelling study Guoao Li, MSa,b ∙ Peng Lu, PhDc ∙ Philip Weinstein, PhDd,e ∙ Aleš Urban, PhDf,g ∙ Shilu Tong, PhDh,i ∙ Niilo Ryti, PhDj,k,l ∙ et al.
The burden of El Niño–Southern Oscillation-related dengue attributable to anthropogenic climate change: a multicountry modelling study
Guoao Li, MSa,b ∙ Peng Lu, PhDc ∙ Philip Weinstein, PhDd,e ∙ Aleš Urban, PhDf,g ∙ Shilu Tong, PhDh,i ∙ Niilo Ryti, PhDj,k,l ∙ et al.
https://www.thelancet.com/journals/lanplh/article/PIIS2542-5196(26)00027-6/fulltext?dgcid=raven_jbs_etoc_feature_lanplh
Drought exposure and the risk of sexual, emotional, and physical violence against adolescents in Zimbabwe, Mozambique, and Lesotho: an observational study Bothaina Eltigani, MBBS MSca Send email to bothaina.eltigani@spi.ox.ac.uk ∙ Roman Hoffmann, PhDb ∙ Prof Lucie Cluver, PhD
Drought exposure and the risk of sexual, emotional, and physical violence against adolescents in Zimbabwe, Mozambique, and Lesotho: an observational study
Bothaina Eltigani, MBBS MSca Send email to bothaina.eltigani@spi.ox.ac.uk ∙ Roman Hoffmann, PhDb ∙ Prof Lucie Cluver, PhD
https://www.thelancet.com/journals/lanplh/article/PIIS2542-5196(26)00021-5/fulltext?dgcid=raven_jbs_etoc_feature_lanplh
Expanded Recommendations for Use of Pneumococcal Conjugate Vaccines Among Adults Aged ≥50 Years: Recommendations of the Advisory Committee on Immunization Practices — United States, 2024 Authors: Miwako Kobayashi, MD; Andrew J. Leidner, PhD; Ryan Gierke, MPH; Wei Xing, MSTAT; Emma Accorsi, PhD; Pedro Moro, MD; Mini Kamboj, MD; George A. Kuchel, MD; Robert Schechter, MD; Jamie Loehr, MD; Adam L. Cohen, MD
Eastern Europe's alcohol-related liver disease crisis is preventable The Lancet Regional Health – Europe + +...
Eastern Europe's alcohol-related liver disease crisis is preventable
The Lancet Regional Health – Europe
https://www.thelancet.com/journals/lanepe/article/PIIS2666-7762(26)00154-7/fulltext?dgcid=raven_jbs_etoc_email
Jun 2026
Volume 65
https://www.thelancet.com/journals/lanepe/issue/vol65nonull/PIIS2666-7762(26)X2002-6
Chronic liver disease in Europe +...
https://www.thelancet.com/series-do/chronic-liver-disease?dgcid=raven_jbs_etoc_feature_lanepecld26
This four-paper Series examines the growing but under-recognised burden of chronic liver disease in Europe, with a focus on metabolic dysfunction-associated steatotic liver disease, steatotic liver disease, alcohol-related liver disease and viral hepatitis. The Series provides country-level data on MASLD policies in Europe, analyses systemic failures in prevention, timely detection, and equitable access to care across diverse populations and health systems; and evaluates policy gaps, health system responses, and innovations in diagnostics, care models, and public health strategies. The Series calls for the rapid integration of metabolic liver health into non-communicable disease frameworks, strengthened surveillance and care pathways, and coordinated, equity-driven, and preventative approaches to identify the “missing millions” and reduce the rising human and economic toll of chronic liver disease across the region.
The promise and perils of AI in oncology The Lancet Oncology ++... ++...
The promise and perils of AI in oncology
The Lancet Oncology
https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00252-4/fulltext?dgcid=raven_jbs_etoc_email
Jun 2026
Volume 27Number 6p649-760, e271-e316
https://www.thelancet.com/journals/lanonc/issue/vol27no6/PIIS1470-2045(26)X2005-8
MRI-guided adaptive radiotherapy for high grade glioma (UNITED): a single-centre, single-arm, non-inferiority, phase 2 trial
Dr Jay S Detsky, MD PhDa Send email to jay.detsky@sunnybrook.ca ∙ Adrian Wai Chan, MDa ∙ Daniel Moore-Palhares, MDa ∙ Amir H Safavi, MDa ∙ James Perry, MDb ∙ Mary Jane Lim Fat, MDb ∙ et al.
https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00088-4/abstract?dgcid=raven_jbs_etoc_feature_lanonc
Cancer workforce—a global crisis
https://www.thelancet.com/commissions-do/cancer-workforce?dgcid=raven_jbs_etoc_feature_lanoncworkforce26
A sufficiently resourced, multidisciplinary, workforce is essential for delivering cancer care and doing clinically relevant research, as well as being a major barrier to reducing disparities in cancer outcomes between high-income and low-income settings. The Lancet Oncology’s Commission on Cancer workforce—a global crisis provides actionable guidance for strengthening the global cancer workforce with an emphasis on reducing global disparities. The Commission models the current and future global landscape of common cancers and workforce personnel types to better understand the extent of the changing global cancer burden and workforce needs. Focusing on examples from sub-Saharan Africa and Latin America, the authors also examine obstacles to workforce development and retention in low-income and middle-income countries and propose pragmatic actions to address the workforce crisis.
June Is CAH Awareness Month by CheckRare Staff| Published on: May 31, 2026
June Is CAH Awareness Month
by CheckRare Staff| Published on: May 31, 2026
June is CAH Awareness Month, a time dedicated to increasing understanding of congenital adrenal hyperplasia (CAH) and supporting the individuals and families impacted by this rare genetic condition. CAH affects the adrenal glands and can interfere with the body’s ability to produce essential hormones, including cortisol and aldosterone. While the condition is rare, early diagnosis and ongoing specialized care can make a significant difference in patient outcomes.
https://checkrare.com/june-is-cah-awareness-month/
Arginine Vasopressin Deficiency (AVP-D) Overview by CheckRare Staff| Published on: Jun 2, 2026
Arginine Vasopressin Deficiency (AVP-D) Overview
by CheckRare Staff| Published on: Jun 2, 2026
Christopher Romero, MD, a pediatric endocrinologist at Mount Sinai Medical Center, New York City, and Associate Professor of Pediatrics at the Icahn School of Medicine at Mount Sinai discusses arginine vasopressin deficiency. The name of the rare disease central diabetes insipidus was changed in 2024 to better reflect its etiology.
https://checkrare.com/overview-of-arginine-vasopressin-deficiency/
Structural shifts and constraints in animal-based neuroscience Mario Treviño* [1] , Oscar Arias-Carrión [2,3]
https://www.academia.edu/3071-4087/2/1/10.20935/AcadNeurosci8190
Animal models have long been central to neuroscience, providing direct experimental access to neural processes underlying perception, action, cognition, and disease. Over the past century, work in non-human primates (NHPs), rodents, and other species has established key principles of neural organization and behavior and has supported much of translational neuroscience. However, the institutional and material conditions that sustain animal-based research are now changing in fundamental ways. Ethical and regulatory requirements have intensified, costs and approval timelines have increased, and global supply chains, particularly for NHPs, have become fragile. In parallel, advances in human neuroscience, stem-cell-derived systems, and computational approaches have matured to the point that they challenge the historical reliance on animals for many classes of questions. These forces are not eliminating animal research, but they are reshaping the conditions under which it remains feasible, competitive, and scientifically justified. In this Perspective, we examine how these converging pressures are reconfiguring animal-based neuroscience. We review long-term trends in animal use and accessibility, highlighting species-specific constraints and emerging geopolitical asymmetries. We then analyze the growing role of alternative and complementary platforms, including human brain organoids, genetically engineered rodents, small primates, and ‘human-centric’ neurophysiological and imaging approaches, emphasizing both their strengths and limitations. Finally, we discuss the implications of this diversification for research planning, training, and scientific organization. We argue that the future of neuroscience will be defined not by the disappearance of animal models, but by their integration into hybrid experimental frameworks that preserve mechanistic rigor while adapting to evolving scientific and societal constraints.
https://www.academia.edu/journals/academia-neuroscience-and-brain-research/articles?source=journal-top-nav
The future of gene therapy depends on mastering in vivo delivery Written byBree Foster, PhD ++ +...
A new marketplace wants to rescue shelved cell and gene therapies
CGTxchange pairs an AI-enabled evaluation platform with ASGCT's global network to connect deprioritized rare disease programs with new sponsors and investors.
Written byAndrea Corona
https://www.drugdiscoverynews.com/a-new-marketplace-wants-to-rescue-shelved-cell-and-gene-therapies-17168?utm_campaign=DDN_Newsletter_Dose&utm_medium=email&_hsenc=p2ANqtz--X0o8KhfjVpmQy5_62TBRWQxPlu2ClDUgJck8RT0QKN_Fd3Tj1SwExV4E6zR3bfMGqiz5ZQ_IGneL0J3gIn3EJnZ_Ktg&_hsmi=421791012&utm_content=421791012&utm_source=hs_email
Hundreds of cell and gene therapies (CGTs) that showed clinical promise have been shelved in recent years — not because they failed patients, but because they failed to meet traditional commercial return expectations. A new joint venture announced January 7, 2026, is attempting to create an alternative pathway for those programs.
The future of gene therapy depends on mastering in vivo delivery
At the Advanced Therapies conference, industry leaders showcased how in vivo CAR T cell and gene delivery innovations could transform accessibility and clinical outcomes.
Written byBree Foster, PhD
https://www.drugdiscoverynews.com/the-future-of-gene-therapy-depends-on-mastering-in-vivo-delivery-17102?utm_campaign=DDN_Newsletter_Dose&utm_medium=email&_hsenc=p2ANqtz-8jvG60X2NblEZzcVMhEvsnl8BHfgmFfsTaTtjIuCWdTiOMGXGtk21XM_s6r5xV2WUP6FBvXRyEwB_8Zqj_8kDKlQaSow&_hsmi=421791012&utm_content=421791012&utm_source=hs_email
Over the past decade, chimeric antigen receptor (CAR) T cell therapy has emerged as one of the most transformative innovations in cancer treatment, harnessing the immune system’s power to target and eliminate malignant cells. By redirecting patient-derived T cells to recognize specific antigens, CAR T therapies have achieved remarkable success in hematologic malignancies, particularly in refractory disease.
7th Edition Live-Cell Imaging and Analysis Handbook — A Companion Guide for Incucyte® Users
https://www.sartorius.com/en/products/live-cell-imaging-analysis/live-cell-analysis-resources/live-cell-imaging-and-analysis-handbook?utm_campaign=DDN_Newsletter_Dose&utm_medium=email&_hsenc=p2ANqtz-_LqYARuUgXMi5GLhoHygO9iDiR8atfv1dglc20Mx9bkcfI6MCfAU1IBuwTzBCKqDtLUVRFVzGJVhKJdXd2yuShTR9Icg&_hsmi=421791012&utm_content=421791012&utm_source=hs_email
How magnetic particle imaging is giving cell therapy a navigation system Scientists at Johns Hopkins used a whole-body imaging technique to track where therapeutic cells go after injection Written byAndrea Corona
https://www.drugdiscoverynews.com/how-magnetic-particle-imaging-is-giving-cell-therapy-a-navigation-system-17200
Cell therapies have transformed treatment for certain blood cancers and hold promise for autoimmune diseases and neurological conditions, but they share a fundamental problem: once therapeutic cells are injected into a patient, clinicians have almost no way to know where they go. Conventional imaging technologies including magnetic resonance imaging (MRI) and computed tomography (CT) cannot reliably visualize the small cell numbers involved in these treatments, leaving researchers without feedback on whether a therapy is reaching its target, how many cells arrive, or why some patients respond and others do not.
Pulmonary Tuberculosis: Developing Drugs for Treatment May 2026
https://www.fda.gov/regulatory-information/search-fda-guidance-documents/pulmonary-tuberculosis-developing-drugs-treatment?utm_medium=email&utm_source=govdelivery
The U.S. Food and Drug Administration (FDA) published a final guidance for industry, “Pulmonary Tuberculosis: Developing Drugs for Treatment,” last month. The guidance aims to assist sponsors in the clinical development of investigational drugs to treat pulmonary tuberculosis (TB), an airborne bacterial infection caused by Mycobacterium tuberculosis (M. tuberculosis) that primarily attacks the lungs.
This guidance addresses FDA’s current thinking regarding the overall development program for a new investigational drug or drugs to be used in combination with approved drugs, or as a new regimen that includes one or more investigational drugs to support a pulmonary TB treatment indication. This guidance finalizes the FDA draft guidance issued on December 15, 2022.
The final guidance includes edits and updated information in the following areas: nonclinical and safety considerations, study populations, efficacy endpoints, and trial design considerations.
Infections caused by M. tuberculosis occur in the United States and are endemic in many parts of the world. Resistance to multiple drugs and coinfection with human immunodeficiency virus (HIV) pose challenges in TB management. Drugs with new mechanisms of action, improved safety profiles, fewer drug-drug interactions, and treatment-shortening combination regimens are needed to manage this infection.
Abivax ulcerative colitis drug shows strong efficacy, but cases of cancer raise concerns The late-stage trial has been closely watched
https://www.statnews.com/2026/06/01/abivax-ulcerative-colitis-obefazimod/
By Elaine ChenJune 1, 2026
Elaine Chen, a national biotech reporter, is the co-author of The Readout, a newsletter about the business, science, and politics of biotech.
NIH research clears way for study of experimental treatment for opioid use disorder IND in effect for human safety study of mitragynine, a kratom isolate.
NIH research clears way for study of experimental treatment for opioid use disorder
IND in effect for human safety study of mitragynine, a kratom isolate.
The National Institutes of Health (NIH) today announced that its Investigational New Drug (IND) application for mitragynine, the primary psychoactive compound found in Mitragyna speciosa (kratom), has taken effect with the U.S. Food and Drug Administration (FDA). The IND paves the way for an NIH-led phase I clinical trial to evaluate mitragynine as a potential treatment for opioid use disorder.
https://www.nih.gov/news-events/news-releases/nih-research-clears-way-study-experimental-treatment-opioid-use-disorder
U.S. Department of Health and Human Services
NATIONAL INSTITUTES OF HEALTH NIH News
National Institutes of Health
NIH RESEARCH CLEARS WAY FOR STUDY OF EXPERIMENTAL TREATMENT FOR OPIOID USE DISORDER
IND in effect for human safety study of mitragynine, a kratom isolate
The National Institutes of Health (NIH) today announced that its Investigational New Drug (IND) application for mitragynine, the primary psychoactive compound found in Mitragyna speciosa (kratom), has taken effect with the U.S. Food and Drug Administration (FDA). The IND paves the way for an NIH-led phase I clinical trial to evaluate mitragynine as a potential treatment for opioid use disorder.
Researchers at NIH and the University of Florida developed the purified formulation of mitragynine to be used in the trial, as well as the preclinical work that led to the submission of the IND application.
“This IND is a major step toward expanding treatment options for the millions of Americans struggling with opioid use disorder, which has contributed to historically high overdose mortality rates,” said Nora Volkow, M.D., director of NIH’s National Institute on Drug Abuse (NIDA).
Interest in kratom, a tropical tree found in southeast Asia, as a treatment for opioid use disorder has increased in recent years, with many reportedly using it for opioid withdrawal, pain, and other conditions as well.
While the kratom plant contains many compounds known to interact with opioid receptors, research indicates that its potential therapeutic effects are likely driven by the slow conversion of mitragynine in the body. Preclinical studies led by scientists at the University of Florida and NIH’s National Center for Advancing Translational Sciences (NCATS) and NIDA have demonstrated that mitragynine administration, across several doses, did not raise significant safety concerns in animal models.
However, the compound in isolation has yet to be studied in humans. With the IND in effect, investigators can now begin that work.
NIH scientists are planning to conduct the first randomized, double-blind, placebo-controlled study to assess the safety and tolerability of the mitragynine formulation in humans.
“We’ve seen the potential of mitragynine in the lab, and now we’re finally able to examine its potential in people. Hopefully this work will lead to a new treatment option for people with opioid use disorder and support a path to recovery,” said NCATS Director Joni Rutter, Ph.D.
The trial is part of the Helping to End Addiction Long-term® Initiative, or NIH HEAL Initiative®
NIH HEAL Initiative and Helping to End Addiction Long-term are registered service marks of the U.S. Department of Health and Human Services.
About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.
NIH...Turning Discovery into Health -- Registered, U.S. Patent and Trademark Office
###
This NIH News Release is available online at:
lunes, 1 de junio de 2026
Transdermal therapy restores anti-tumor immunity in bladder cancer models Preclinical data show a first-in-class transdermal bicarbonate therapy increases tumor pH, reactivates T cells and slows bladder tumor growth in mice. Written byBree Foster, PhD
https://www.drugdiscoverynews.com/transdermal-therapy-restores-anti-tumor-immunity-in-bladder-cancer-models-17130?utm_campaign=DDN_Newsletter_Dose&utm_medium=email&_hsenc=p2ANqtz-8hqc-9yKHZT2lCilX8RCCpFnJ_xs1pT47e78Kdigr9r3a84LdWU26PMomwdGq4LAOTpXRlwrVdsPHJN_VMEoJJ3fmbog&_hsmi=421619108&utm_content=421619108&utm_source=hs_email
Extracellular acidity is a common feature of many solid tumors, similar to hypoxia. Increased metabolic rates, higher glycolysis and inadequate vasculature all contribute to the accumulation of acid in the tumor microenvironment (TME). This aspect is also one of their most effective defenses.
Driven by altered metabolism and poor perfusion, the acidic TME suppresses immune cell function, promotes treatment resistance, and enables disease progression. While buffering tumor pH has shown promise in preclinical studies, translating this strategy into the clinic has proven elusive.
What does it mean when lupus goes quiet? A $15 million international study is investigating patients in long-term remission to understand whether lupus can truly switch off — and what that reveals about the immune system. Written byBree Foster, PhD
https://www.drugdiscoverynews.com/what-does-it-mean-when-lupus-goes-quiet-17178?utm_campaign=DDN_Newsletter_Dose&utm_medium=email&_hsenc=p2ANqtz-8oA7XCbFvEt8mWN5SzictbeSsPi0si3EgZ_Wf_df1FQMvHSS7Bl8CGvQbW_UmwrAKXNApL2pVOQkr2iIQUFrqT2fMjSA&_hsmi=421619108&utm_content=421619108&utm_source=hs_email
When Hazel Harris was diagnosed with systemic lupus erythematosus (SLE) in 1986, she had never heard of the disease. She was 33 years old, busy, energetic, and always on the move. Then her body began to change in ways she couldn’t explain.
First came the rash on her face, in the shape of a butterfly. Then her eyes grew puffy. This was followed by a deep fatigue that was extremely unlike her. Finally, her leg began to swell so badly that she could no longer walk. “That’s when I had no choice but to go to the doctor,” she told DDN.
SLE is a chronic autoimmune disease in which the immune system attacks the body’s own tissues, causing inflammation that can affect the skin, joints, kidneys, lungs, brain, blood vessels, and heart. It affects approximately 3.4 million people worldwide, most commonly women, and disproportionately people of African ancestry.
An AI model decodes tumor mutations to predict treatment response Trained on more than 30,000 tumor genomes, MutationProjector offers drug developers a broader framework for connecting cancer genetics to therapy outcomes. Written byAndrea Corona
https://www.drugdiscoverynews.com/an-ai-model-decodes-tumor-mutations-to-predict-treatment-response-17197
Genetic sequencing has become a routine part of cancer care, but making clinical sense of the thousands of mutations found in a given tumor remains a stubborn challenge. A new AI model from researchers at University of California, San Diego (UC San Diego) is designed to close that gap — and it could have meaningful implications for how drug developers think about patient stratification and biomarker discovery.
Reminder: Informed Care in Psychiatric Medication Use and Withdrawal Webinar Wednesday, June 3, 2-3:30 p.m. ET
https://zoom.us/webinar/register/WN_A_RgmmwtTy2lY22iGnmvoA?utm_source=SAMHSA&utm_campaign=966130a5b6-EMAIL_CAMPAIGN_2026_05_11_01_40_COPY_01&utm_medium=email&utm_term=0_-a9ce11e3ce-167840245#/registration
SAMHSA’s Office of the Chief Medical Officer will host a webinar titled “Informed Care in Psychiatric Medication Use and Withdrawal”. The event will feature Matthew Rudorfer, MD; Mark Horowitz, MD, PhD; and Laura Delano. The webinar will explore a range of psychiatric treatment options and strategies to support fully informed care, including understanding benefits, potential risks, dependence, and withdrawal considerations. Presenters will discuss emerging perspectives in the field, highlight current evidence, and examine approaches that promote collaborative decision-making between providers and patients. Following the presentations, attendees will have the opportunity to participate in a moderated question-and-answer segment. Questions will be addressed in the order received, with priority given to those submitted during registration. The webinar is open to all, but registration is required.
Presenters:
Matthew Rudorfer, M.D., is Chief of the Psychopharmacology, Somatic, and Integrated Treatments Research Program in the Treatment and Preventive Interventions Research Branch within the Division of Services and Intervention Research at the National Institute of Mental Health.
Mark Horowitz, M.D., Ph.D., is an Associate Professor of Psychiatry at the University of Adelaide, a Visiting Lecturer in Psychopharmacology at King’s College London, and the lead of the National Psychotropic Deprescribing Clinic within the United Kingdom’s National Health Service.
Laura Delano is an author, speaker, and consultant, and the founder of Inner Compass Initiative, a nonprofit organization that supports informed decision-making about psychiatric drugs and promotes non-medicalized approaches to human distress.
In support of improving patient care, the Substance Abuse and Mental Health Services Administration is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide interprofessional collaborative continuing education (IPCE) activities for the healthcare team.
IPCE activity credits are accepted as CME for medical practitioners, and CE for dieticians, nurses, pharmacists, physician associates/physician assistants, psychologists, and social workers. The activity was planned by and for the healthcare team. Please note: Organizations, not individual courses, are approved under this program. Regulatory boards are the final authority on courses accepted for continuing education credit.
As a Jointly Accredited Organization, the Substance Abuse and Mental Health Services Administration is approved to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Organizations, not individual courses, are approved under this program. Regulatory boards are the final authority on courses accepted for continuing education credit. Social workers completing this course receive 1.0 CEU continuing education credits.
Continuing Education (CE) credits for psychologists are provided through the co-sponsorship of the American Psychological Association (APA) Office of Continuing Education in Psychology (CEP). The APA CEP Office maintains responsibility for the content of the programs.
The views, opinions, and content expressed in this presentation do not necessarily reflect the views, opinions, or policies of the Substance Abuse and Mental Health Services Administration or the U.S. Department of Health and Human Services (HHS).
A Home for Every Child Innovation Challenge
The Administration for Children and Families (ACF) at the U.S. Department of Health and Human Services has announced a nationwide $7 million prize competition aimed at incentivizing states to improve their ratios of foster homes-to-children in foster care. This challenge supports ACF's "A Home for Every Child" initiative, which aims to right-size the ratio of available foster homes to the number of children in the foster care system nationwide.
The objective is to recognize and reward states that demonstrate exceptional progress in increasing available foster homes relative to children in care, thereby advancing the goal of having homes waiting for children rather than children waiting for homes. These state performance-based bonuses reflect ACF’s commitment to achieving the goal of a 1:1 ratio of foster homes-to-children in foster care across the country.
The Challenge Period is October 1, 2026 - September 30, 2027.
https://acf.gov/home-every-child-innovation-challenge?utm_medium=email&utm_source=govdelivery
Understanding the Requirements for Sickle Cell Disease Comprehensive Systems of Care June 18, 2026: 2 - 3:30 PM ET / 1 - 2:30 PM CT
https://events.gcc.teams.microsoft.com/event/8433102f-32e8-479c-8970-466dea77048e@d58addea-5053-4a80-8499-ba4d944910df?utm_medium=email&utm_source=govdelivery
Join the U.S. Department of Health & Human Services (HHS) Office of Minority Health (OMH) for Federal Resources and Efforts to Advance Sickle Cell Disease Comprehensive Systems of Care, part two of a roundtable series focused on advancing comprehensive systems of care for sickle cell disease (SCD). A comprehensive system of care for SCD offers multidisciplinary and specialized healthcare services to the SCD community throughout the lifespan. This webinar will provide information about available resources and specific efforts across HHS, and address challenges highlighted during Roundtable 1 in achieving sickle cell disease comprehensive systems of care.
Provisional Drug Overdose Death Counts +...
https://www.cdc.gov/nchs/nvss/vsrr/drug-overdose-data.htm?ACSTrackingID=DM155304&ACSTrackingLabel=Mental+Health%2C+Prevention%2C+and+the+Latest+Overdose+Data+&deliveryName=DM155304&utm_medium=email&utm_source=govdelivery
The latest provisional data show 69,973 predicted overdose deaths for the 12-month period ending in December 2025 — about a 14% decrease compared with the same period ending in December 2024.
Monthly provisional data suggest overdose deaths were relatively stable from September 2024 through July 2025, decreased in August and September 2025, and then leveled in October 2025.
Most states saw decreases in predicted overdose deaths when comparing full-year 2025 with full-year 2024. However, several states — particularly in the Southwest and West — experienced increases during late 2024 and much of 2025.
HRSA Highlights Opportunities for Health Centers to Advance Nutrition-Focused Care to Prevent Chronic Disease U.S. Department of Health and Human Services Health Resources and Services Administration For Immediate Release May 13, 2026
https://www.hrsa.gov/about/news/press-releases/nutrition-care-prevent-chronic-disease?utm_medium=email&utm_source=govdelivery
The Health Resources and Services Administration (HRSA) issued a Dear Colleague Letter encouraging more than 1,400 HRSA-funded health centers nationwide to expand efforts to promote proper nutrition as part of the Administration’s broader Make America Healthy Again (MAHA) initiative. Health centers are focused on addressing the root causes of illness and play a pivotal role in chronic disease prevention and treatment—assessing weight, providing nutrition counseling, and helping more than 32 million patients achieve better health outcomes, including control of their diabetes and hypertension.
Sickle Cell Disease - World Sickle Cell Day is June 19 +... +... +
https://minorityhealth.hhs.gov/sickle-cell-disease?utm_medium=email&utm_source=govdelivery
World Sickle Cell Day is observed annually with the goal to increase public knowledge and an understanding of sickle cell disease, and the challenges experienced by patients and their families and caregivers.
Sickle cell disease (SCD) is a complex group of inherited red blood cell disorders that can cause serious health complications such as pain crises, infections, and stroke. In individuals with SCD, the red blood cells become hard, sticky, and sickle (crescent) shaped, which can block blood flow in small blood vessels. SCD affects about 100,000 people in the United States, the majority of whom are black or African American.
This year, the U.S. Department of Health and Human Services’ (HHS) call for a healthier Nation highlights the importance of chronic disease prevention and health promotion, emphasizing the need to address high rates of chronic illness through a range of solutions, including the critical role of food and nutrition. High quality nutrition is essential for individuals living with sickle cell disease (SCD) as it supports their immune system, overall health, and disease management. High-quality nutrition can make a meaningful difference in the lives of people living with SCD.
https://minorityhealth.hhs.gov/news/promoting-good-nutrition-people-sickle-cell-disease?utm_medium=email&utm_source=govdelivery
Learn about the importance of a healthy diet for those living with SCD and view easy to make nutrient-dense recipes.
https://minorityhealth.hhs.gov/news/promoting-good-nutrition-people-sickle-cell-disease?utm_medium=email&utm_source=govdelivery#recipes
What is MyHealthfinder? Trusted information to help your family stay healthy. +... +...
https://odphp.health.gov/myhealthfinder?utm_medium=email&utm_source=govdelivery
The Harms of Screen Use
https://www.hhs.gov/surgeongeneral/reports-and-publications/screen-use-harms/index.html?utm_medium=email&utm_source=govdelivery
Harmful screen use among children and adolescents has become a public health concern. With support from schools, communities, and governments, together we can shift the cultural norms around screens and help our children be healthier and happier nationwide.
Men's Health Week: June 14-21, 2026 +++...+...
https://odphp.health.gov/healthypeople/objectives-and-data/browse-objectives/men?utm_medium=email&utm_source=govdelivery
Healthy People 2030 focuses on improving men's health. Men live an average of 5 years less than women, often dying from preventable or treatable chronic disease related outcomes such as heart disease, cancer, diabetes, and stroke. Men are at higher risk than women for many serious diseases, including heart disease, lung cancer, and HIV. Men also face unique health problems that don’t affect women, like prostate cancer.
https://www.cdc.gov/chronic-disease/prevention/index.html?utm_medium=email&utm_source=govdelivery
To improve men’s health, it’s important to raise awareness about preventive screenings and regular health care for men of all ages. Early detection and treatment, connection and support, and taking preventive steps now can improve health outcomes for men. Interventions to reduce smoking and drinking and promote healthy behaviors also can help prevent diseases and improve men’s health.
https://menshealthmonth.org/?utm_medium=email&utm_source=govdelivery
This year’s theme —“Partners in Care: For Better Lifespans Across the Lifespan” emphasizes that men’s health does not happen in isolation and highlights the role that families, communities, and care partners play in supporting healthier outcomes for men. Fostering men's health throughout the lifespan helps improve outcomes not only for men, but for their families and communities as well. This year, in honor of Men's Health month, consider wearing blue on Fridays in June to show support for men's mental and physical health and encourage the men in your life to seek preventive care.
https://menshealthmonth.org/wp-content/uploads/2026/03/Mens-Health-Month-2026-toolkit-compress.pdf?utm_medium=email&utm_source=govdelivery
domingo, 31 de mayo de 2026
Tracking Key Mental Health and Substance Use Policy Actions Under the Trump Administration Authors: Nirmita Panchal and Heather Saunders Published: May 26, 2026
https://www.kff.org/mental-health/tracking-key-mental-health-and-substance-use-policy-actions-under-the-trump-administration/
In 2024, over 61 million adults in the U.S. experienced a mental illness and deaths due to suicide, gun violence, and drug overdose remained high. Additionally, the COVID-19 pandemic and necessary public health responses exacerbated an already existing mental health and substance use crises. At the same time, many people experience difficulties affording mental health treatment or finding providers. Among insured adults who described their mental health as fair or poor, 43% reported at least one time in the past year when they needed mental health services or medication but did not receive them; some groups – including communities of color, youth and young adults – experience greater barriers.
Hantavirus Outbreak Revives COVID-Era False Health Claims Joel Luther , Hagere Yilma , and Irving Washington
https://www.kff.org/health-information-trust/hantavirus-outbreak-revives-covid-era-false-health-claims/
A hantavirus outbreak linked to a Dutch cruise ship in early May was followed by false health claims that mirror patterns documented in previous outbreaks. The Monitor also examines a new analysis of Americans’ relationship with health and wellness influencers.
New Ebola Quarantine Rule Bars Entry of Noncitizens, Including Green Card Holders, from Affected Countries Published: May 29, 2026
https://www.kff.org/quick-insights/new-ebola-quarantine-rule-bars-entry-of-noncitizens-including-green-card-holders-from-affected-countries/
The rule is significantly more restrictive than approaches used to mitigate risks during past Ebola outbreaks and creates a standing administrative authority that may allow the CDC to quickly issue suspensions or place strict restrictions on entry of any noncitizen, including lawful permanent residents, under situations it deems to be high-risk public health emergencies in the future.
Revolution Medicines starts shipping experimental pancreatic cancer drug Life-extending data for daraxonrasib create high patient demand even without FDA approval
https://www.statnews.com/2026/05/30/pancreatic-cancer-daraxonrasib-revolution-medicines-early-access-asco-2026/
By Adam FeuersteinMay 30, 2026
Adam Feuerstein, a senior writer and biotech columnist, is the author of Adam’s Biotech Scorecard, a subscriber-only newsletter about the crossroads of drug development, business, Wall Street, and biotechnology.
For prostate cancer patients set on surgery, new hormone regimen may improve outcomes, study finds Protocol could become a third option for high risk, early stage cases
https://www.statnews.com/2026/05/31/prostate-cancer-hormone-therapy-cut-relapse-asco-2026/
By Angus ChenMay 31, 2026
Cancer Reporter
Akeso and Summit’s ivonescimab extends survival in squamous cell lung cancer ‘Two drugs in one’ candidate, developed in China, is a highlight at ASCO
https://www.statnews.com/2026/05/31/squamous-cell-lung-cancer-akeso-summit-harmoni-asco-2026/
By Matthew HerperMay 31, 2026
Senior Writer, Medicine, Editorial Director of Events
Practice-changing results reported for Revolution Medicines pancreatic cancer drug Daraxonrasib nearly doubled survival time compared to standard chemotherapy
https://www.statnews.com/2026/05/31/pancreatic-cancer-daraxonrasib-revolution-medicines-results-asco-2026/
By Adam FeuersteinMay 31, 2026
Senior Writer, Biotech
Medscape Medical News Conference News ASCO 2026 Selpercatinib Cuts Recurrence Risk in Early RET+ Non-Small Cell Lung Cancer Will Pass May 31, 2026
https://www.medscape.com/viewarticle/selpercatinib-cuts-recurrence-risk-early-ret-non-small-cell-2026a1000i25
Adjuvant selpercatinib improves event-free survival (EFS) in patients with early-stage, RET fusion-positive non-small cell lung cancer (NSCLC) who have undergone definitive surgery or radiation, based on results of the first phase 3 trial to use a RET inhibitor as adjuvant therapy.
https://www.medscape.com/c25/p14/american-society-clinical-oncology-asco-2026-2026a1000c7g
IMPACT EBC: IMPlementing Advances in Cancer Treatment for Patients With HR+/HER2- Early Breast Cancer - Moving Patient Care Forward
IMPACT EBC: IMPlementing Advances in Cancer Treatment for Patients With HR+/HER2- Early Breast Cancer - Moving Patient Care Forward
Approximately 30% of patients with early breast cancer (EBC) will eventually develop metastatic disease. In hormone receptor (HR)-positive breast cancer, approximately 50% of recurrences occurs within 5 years of diagnosis. Many factors should be considered when evaluating a patient's risk of recurrence, including HR status, and human epidermal growth factor receptor 2 (HER2) status, nodal involvement, histologic grade, anatomic stage, positive or close margins, proliferate rate, tumor size, and the patient's age and health status.
IMPlementing Advances in Cancer Treatment for Patients With HR-Positive, HER2-Negative Early Breast Cancer is a collection of educational programs designed for clinicians to stay up to date on the clinical data that supports decision-making for patients with HR-positive, HER2-negative EBC at risk of recurrence and make an IMPACT on patient outcomes and quality of life.
https://www.medscape.org/advances/implementing-advances-cancer-treatment-patients-hr-her2-2025a1000yzz
Editorial p365 Putting placebo effects in a new light The Lancet Psychiatry +... + + +...
Editorial
p365
Putting placebo effects in a new light
The Lancet Psychiatry
https://www.thelancet.com/journals/lanpsy/issue/vol13no5/PIIS2215-0366(26)X2003-X
Confirmatory efficacy and safety trial of magnetic seizure therapy versus right unilateral ultra-brief electroconvulsive therapy in depression (CREST–MST): a randomised, double-blind, non-inferiority trial in Canada and the USA
Prof Daniel M Blumberger, MDa,b Send email to daniel.blumberger@camh.ca ∙ Prof Shawn M McClintock, PhDe,f ∙ Kevin E Thorpe, MMathc,g ∙ Prof Carol A Tamminga, MDe ∙ Karen Foleyd,h ∙ Prof Mustafa M Husain, MDe ∙ et al.
https://www.thelancet.com/journals/lanpsy/article/PIIS2215-0366(26)00060-X/fulltext?dgcid=hubspot_email_infocusalerts-psychiatry_feature&utm_campaign=infocusalerts-psychiatry&utm_medium=email&_hsenc=p2ANqtz-_rIMPVmPSlOLAsVVcU_fgdNunUrJJtq6bKqVfIK3Hp2taBPEDB92YuVjoTu_WWwF4ppAdFmLLTagrvklWHUNbWO4t5Kg&_hsmi=421429175&utm_content=420563001&utm_source=hs_email
The effectiveness of psychosocial interventions for self-harm in males compared to females: a systematic review and meta-analysis
Oliver Matias Send email to Oliver.Matias@citystgeorges.ac.uk ∙ Alexandra E. Bakou ∙ Kirsten Barnicot ∙ Rose McCabe
https://www.thelancet.com/journals/lanepe/article/PIIS2666-7762(26)00018-9/fulltext?dgcid=hubspot_email_infocusalerts-psychiatry_feature&utm_campaign=infocusalerts-psychiatry&utm_medium=email&_hsenc=p2ANqtz--Z8g6L-OgGMy0jkBb4veLLRUa1Hg9ICUoqTW-j4lcXox1np6FUrup3WHs-vrfkBieZlC7MHVUDG7hkdmDPd69zNDFxBg&_hsmi=421429175&utm_content=420563001&utm_source=hs_email
Editorial
Humanity first, not country first
The Lancet Regional Health – Europe
https://www.thelancet.com/journals/lanepe/issue/vol63nonull/PIIS2666-7762(25)X0014-4
Gene clock predicts time to death in humans — and assesses ‘biological’ age Cellular-ageing clocks based on gene activity could be more sensitive than previous measures. By Heidi Ledford
https://www.nature.com/articles/d41586-026-01661-y?utm_source=Live+Audience&utm_campaign=2f2a6b7480-nature-briefing-daily-20260527_COPY_01&utm_medium=email&utm_term=0_-33f35e09ea-50432164
A powerful molecular clock calibrated using data on gene activity from thousands of individuals can predict biological ageing in rodents, monkeys and humans — and time to death in people1.
FDA approves durvalumab in combination with Bacillus Calmette-Guerin for high-risk non-muscle invasive bladder cancer
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-durvalumab-combination-bacillus-calmette-guerin-high-risk-non-muscle-invasive-bladder
On May 28, 2026, the Food and Drug Administration approved durvalumab (Imfinzi, AstraZeneca) in combination with Bacillus Calmette-Guerin (BCG) for the treatment of adult patients with BCG-naïve, high-risk non-muscle invasive bladder cancer (NMIBC).
sábado, 30 de mayo de 2026
New approach helps design better antibiotics to fight drug-resistant infections
https://www.news-medical.net/news/20260529/New-approach-helps-design-better-antibiotics-to-fight-drug-resistant-infections.aspx
A new way of designing antibiotics could support the discovery of new treatments for drug-resistant infections.
It could also help revive antibiotics that have lost effectiveness because bacteria have evolved over time to survive the drugs meant to kill them.
Novel therapeutic agent proposed to combat drug resistant tuberculosis
https://www.news-medical.net/news/20260529/Novel-therapeutic-agent-proposed-to-combat-drug-resistant-tuberculosis.aspx
A research team led by Associate Professor Noriyuki Kurita from the Department of Computer Science and Engineering at Toyohashi University of Technology and by Associate Professor Pornpan Pungpo from Ubon Ratchathani University in Thailand has proposed a novel therapeutic agent for tuberculosis, using high-precision molecular simulation techniques. The proposed drug is anticipated to bind strongly to the drug-metabolizing enzyme cytochrome P450 (CYP), thereby inhibiting excessive CYP-mediated metabolism and preventing the degradation of co-administered drugs. Additionally, because this agent targets enzymes released by the tuberculosis bacterium rather than the bacterium itself, the likelihood of bacterial mutation and resistance development is reduced, suggesting sustained therapeutic efficacy over an extended period.
Targeted therapy sunvozertinib outperforms standard chemotherapy in advanced lung cancer trial
https://www.news-medical.net/news/20260529/Targeted-therapy-sunvozertinib-outperforms-standard-chemotherapy-in-advanced-lung-cancer-trial.aspx
The targeted therapy sunvozertinib was more effective than standard platinum-based chemotherapy as a first-line treatment for patients with advanced non-small cell lung cancer (NSCLC) driven by EGFR exon 20 insertion mutations (EGFR exon20ins), according to new research from The University of Texas MD Anderson Cancer Center.
Consumer wearables become the new gatekeepers of clinical health care
https://www.news-medical.net/news/20260529/Consumer-wearables-become-the-new-gatekeepers-of-clinical-health-care.aspx
JMIR Publications today released a News and Perspectives expert analysis on consumer wearable platforms' forays into the clinical health care space. Authored by MedTech expert Blythe Karow, MBA, "Meet the New Health Care Gatekeeper: Your Wearable" lays out the implications of wearable tech companies owning the first conversation about a patient's health, as well as the potential impacts on patient trust, policy, and regulation.
Teclistamab delivers deeper responses in relapsed myeloma patients
https://www.news-medical.net/news/20260529/Teclistamab-delivers-deeper-responses-in-relapsed-myeloma-patients.aspx
Patients with relapsed multiple myeloma treated with the immunotherapy teclistamab lived significantly longer and remained in remission far longer than those receiving standard therapies, according to results from a major international phase 3 clinical trial published in The New England Journal of Medicine and presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting.
Thyroid function linked to chronotype or daytime sleepiness in women with Hashimoto's thyroiditis
https://www.news-medical.net/news/20260529/Thyroid-function-linked-to-chronotype-or-daytime-sleepiness-in-women-with-Hashimotos-thyroiditis.aspx
Hashimoto's thyroiditis (HT), an autoimmune disease with a prevalence 2–7 times higher in women than in men, is associated with daytime sleepiness. The present study aimed to test the hypothesis that thyroid function is associated with chronotype and daytime sleepiness in women with HT.
Gene test helps many breast cancer patients avoid chemotherapy
https://www.news-medical.net/news/20260529/Gene-test-helps-many-breast-cancer-patients-avoid-chemotherapy.aspx
Many people with breast cancer can safely avoid chemotherapy with the use of a gene test, potentially sparing them unnecessary side effects without increasing the risk of the cancer returning, a large international clinical trial led by UCL has found.
The OPTIMA trial (Optimal Personalised Treatment of early breast cancer using Multi-parameter Analysis) was designed to reduce the use of unnecessary chemotherapy for people with newly diagnosed breast cancer. It followed more than 4,400 patients across the UK, Norway, Sweden, Australia, New Zealand and Thailand.
Pembrolizumab combination therapy improves survival in recurrent endometrial cancer patients
https://www.news-medical.net/news/20260529/Pembrolizumab-combination-therapy-improves-survival-in-recurrent-endometrial-cancer-patients.aspx
Previously, immature overall survival results of the NRG Oncology GY018 (NRG-GY018) trial suggested that the use of the immunotherapy drug pembrolizumab in combination with chemotherapy improved overall survival for patients with advanced stage or recurrent endometrial cancer when compared to chemotherapy alone. Notably, this benefit was observed in both the mismatch repair proficient (pMMR) and mismatch repair deficient (dMMR) populations. An analysis of the study data, with prolonged follow-up, demonstrated that there was a sustained numerical benefit in overall survival for patients who received pembrolizumab with chemotherapy even when a large proportion of the initial placebo treated patients received post-protocol immunotherapy. These results were presented during the Gynecologic Oncology Session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting.
Researchers uncover new clues about the origin of Alzheimer's tau tangles
https://www.news-medical.net/news/20260529/Researchers-uncover-new-clues-about-the-origin-of-Alzheimers-tau-tangles.aspx
Researchers at Columbia University have uncovered new clues about the earliest molecular events that may trigger Alzheimer's disease, shedding light on how toxic tau filaments begin to form in the brain. The findings could help guide future therapies aimed at stopping the disease before significant memory loss and cognitive decline occur.
Fruit fly study links dopamine to stress-induced sexual dysfunction
https://www.news-medical.net/news/20260530/Fruit-fly-study-links-dopamine-to-stress-induced-sexual-dysfunction.aspx
Scientists from Tokyo Metropolitan University have revealed key parts of the biochemical pathways connecting stress to sexual dysfunction. By studying Drosophila fruit flies, they showed that the neurotransmitter dopamine was responsible for determining how long male flies showed persistent courtship suppression after being confined in a small space, but not whether mating was suppressed in the first place. Their findings in a key model organism illuminate neurobiological factors causing sexual dysfunction in other organisms, including humans.
Could guava juice help prevent anemia?
https://www.news-medical.net/news/20260529/Could-guava-juice-help-prevent-anemia.aspx
An inexpensive tropical fruit may help tackle one of the world's most common nutritional deficiencies, with researchers finding that guava juice can significantly improve hemoglobin levels in women and girls.
A systematic review from Indonesia, published in the journal BMJ Nutrition, Prevention & Health, indicates that adding guava juice to the diet could boost hemoglobin levels in adolescent girls and pregnant women. This could potentially offer a low-cost dietary complement to iron supplementation, given the high prevalence of iron-deficiency anemia among females, especially in low- and middle-income countries (LMICs).
Making older women more visible in healthy ageing The Lancet Regional Health – Western Pacific ++... ++
Making older women more visible in healthy ageing
The Lancet Regional Health – Western Pacific
https://www.thelancet.com/journals/lanwpc/article/PIIS2666-6065(26)00095-7/fulltext
May 2026
Volume 70
https://www.thelancet.com/journals/lanwpc/issue/vol70nonull/PIIS2666-6065(26)X2003-X
Adaptive functioning in school-aged children with spinal muscular atrophy in the treatment era: a non-randomised cohort study
Emily E. Faraha ∙ Sarah-Grace Paguintoa,c ∙ Melissa R. Mandarakasa,b ∙ Karen Herberta,b ∙ Smriti Krishand ∙ Hugo Sampaiob ∙ et al.
https://www.thelancet.com/journals/lanwpc/article/PIIS2666-6065(26)00070-2/fulltext?dgcid=raven_jbs_etoc_feature_lanwpc
Critical care access and outcomes in residents of inpatient-care catchment areas with and without ICUs: a nationwide cohort study in Japan
Hiroyuki Ohbea,b Send email to hohbey@gmail.com ∙ Nobuaki Shimec ∙ Kei Nishiyamad ∙ Takuya Satoe ∙ Kent Doie ∙ Kiyohide Fushimif ∙ et al.
https://www.thelancet.com/journals/lanwpc/article/PIIS2666-6065(26)00072-6/fulltext?dgcid=raven_jbs_etoc_feature_lanwpc
Editorial p2141 A new era in neurology The Lancet + +... + +
Comparison of [18F]flortaucipir and [18F]MK6240 for the detection of tau pathology in Alzheimer's disease (HEAD): a multicentre, prospective, cross-sectional, within-participant study
Guilherme Povala, PhDa,* ∙ Bruna Bellaver, PhDa,* ∙ Firoza Z Lussier, MSa ∙ Livia Amaral, MSa ∙ Guilherme Bauer-Negrini, PhDa ∙ Pamela C L Ferreira, PhDa ∙ et al.
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)00417-4/fulltext?dgcid=hubspot_email_infocusalerts-neurology_feature_lancetneuro26&utm_campaign=infocusalerts-neurology&utm_medium=email&_hsenc=p2ANqtz-8ujTQJDAYhslHYBGpDUpx_0K9Os9kmp4PeAcWF_2cuB18ftCv178Pqz1vfY_YQeOAe2ZXPwgzy1Rc4OhQ7sVseVHNJ4g&_hsmi=421331774&utm_content=420563000&utm_source=hs_email
Editorial
p2141
A new era in neurology
The Lancet
https://www.thelancet.com/journals/lancet/issue/vol407no10544/PIIS0140-6736(26)X2019-0
Alzheimer's disease
Alberto Serrano-Pozo, MD PhDa,b,c Send email to aserrano1@mgh.harvard.edu ∙ Prof Valentina Escott-Price, PhDd,e ∙ Prof Lea T Grinberg, MD PhDf ∙ Tharick Pascoal, MD PhDg,h ∙ Marc Suárez-Calvet, MD PhDi,j ∙ Prof Bruno Dubois, MDk,l ∙ et al.
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)00198-4/abstract?utm_campaign=infocusalerts-neurology&utm_medium=email&dgcid=hubspot_email_infocusalerts-neurology_feature_lancetneuro26&_hsenc=p2ANqtz-9k3jQnYevg0uj5SxI80gLmEfvlwjqHWAJYtswfqGMfseP5cQL0HW6IdEf9fVGrTyGlMLAlvimkY2sVkLdOyypZB_YllA&_hsmi=421331774&utm_content=420563000&utm_source=hs_email
Integrating peripheral immune control and brain health in the multiple sclerosis continuum
Eleonora Cocco
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)00829-9/abstract?utm_campaign=infocusalerts-neurology&utm_medium=email&dgcid=hubspot_email_infocusalerts-neurology_feature_lancetneuro26&_hsenc=p2ANqtz-8GWqCa3ivRgyNXD2SXoIwEPV0MBEjA9PEJArb61cwurvs-NTfuKQ-qNhY8dWMK4FM6GUMrdaRKd4NkFa8zVm2ojHoviQ&_hsmi=421331774&utm_content=420563000&utm_source=hs_email
Tile-Based Radiation to Treat Large Brain Metastases? M. Alexander Otto, PA, MMSc May 30, 2026
https://www.medscape.com/viewarticle/tile-based-radiation-treat-large-brain-metastases-2026a1000i1s
A radiation therapy implant demonstrated significantly improved surgical bed control and longer overall survival compared to standard stereotactic radiotherapy (SRT) after resection of large brain metastases, according to a phase 3 trial.
https://www.medscape.com/c25/p14/american-society-clinical-oncology-asco-2026-2026a1000c7g
Tafasitamab Combo Boosts R-CHOP in Frontline DLBCL M. Alexander Otto, PA, MMSc May 30, 2026
https://www.medscape.com/viewarticle/tafasitamab-combo-boosts-r-chop-frontline-dlbcl-2026a1000i14
Adding tafasitamab and lenalidomide to rituximab, cyclophosphamide, hydroxydaunomycin, oncovin, and prednisone (R-CHOP) improves outcomes in newly diagnosed diffuse large B-cell lymphoma and high-grade B-cell lymphoma, according to the phase 3 frontMIND trial.
https://www.medscape.com/c25/p14/american-society-clinical-oncology-asco-2026-2026a1000c7g
More Patients With Breast Cancer Can Skip Axillary Dissection Will Pass May 30, 2026
https://www.medscape.com/viewarticle/more-patients-breast-cancer-can-skip-axillary-dissection-2026a1000i1u
Women with breast cancer and 1-2 sentinel lymph node macrometastases can safely skip completion axillary lymph node dissection (ALND) without compromising overall survival or arm function, according to new data from the largest randomized trial of its kind to date.
The Potential for Remission, Cure in Psoriasis With Biologic Treatment: A Q&A With Andrew Blauvelt, MD, MBA Christine Kilgore May 27, 2026 ++++ ++++
The Potential for Remission, Cure in Psoriasis With Biologic Treatment: A Q&A With Andrew Blauvelt, MD, MBA
Christine Kilgore
https://www.medscape.com/viewarticle/potential-remission-cure-psoriasis-biologic-treatment-q-2026a1000hlg?ecd=mkm_ret_260530_mscpmrk_derm_biologics-in-derm_etid8382686&uac=148436CN&impID=8382686
May 27, 2026
Andrew Blauvelt, MD, MBA, began to study psoriasis in depth in Portland, Oregon, over 20 years ago, after spending several years at the National Institutes of Health training in cellular immunology and working as a senior investigator on HIV. In Portland, he was a professor at Oregon Health & Science University, where he conducted basic science research on the immunology of psoriasis, with a focus on how interleukin (IL)-23 and Th17 cells contribute to psoriasis pathogenesis.
Biologics Continue to Transform Psoriasis Care, Giving Physicians and Patients More Options
Damian McNamara, MA
https://www.medscape.com/viewarticle/biologics-continue-transform-psoriasis-care-giving-2026a1000hs6?ecd=mkm_ret_260530_mscpmrk_derm_biologics-in-derm_etid8382686&uac=148436CN&impID=8382686
May 28, 2026
This is the second installment of a four-part series on biologics and dermatology, further exploring the impact of biologics in the treatment of dermatologic diseases. Future installments will focus on atopic dermatitis and other skin diseases.
Exciting Developments in Psoriasis From AAD 2026
Shawn G. Kwatra, MD
https://www.medscape.com/viewarticle/updates-psoriasis-and-related-disorders-aad-2026-2026a10008be?ecd=mkm_ret_260530_mscpmrk_derm_biologics-in-derm_etid8382686&uac=148436CN&impID=8382686
Clinical Impact of AAD 2026: Integrating Weight Management into Psoriasis Care
Tina Bhutani, MD, MAS
https://www.medscape.com/viewarticle/mdangle-aad-2026-psoriasis-clinical-impact-2026a10005ba?ecd=mkm_ret_260530_mscpmrk_derm_biologics-in-derm_etid8382686&uac=148436CN&impID=8382686
Expert Guidance on Switching, Stacking Systemic Therapies for Psoriasis
Damian McNamara, MA
https://www.medscape.com/viewarticle/expert-guidance-switching-stacking-systemic-therapies-2026a1000gyp?ecd=mkm_ret_260530_mscpmrk_derm_biologics-in-derm_etid8382686&uac=148436CN&impID=8382686
May 25, 2026
How Much Monitoring Is Enough in Psoriasis Care?
Steven R. Feldman, MD, PhD; Jennifer C. Cather, MD; Brad P. Glick, DO, MPH, FAAD, FAOCD
https://www.medscape.com/ca8/p04/podcast-psoriasis-s4-ep3-2026a10006hk?ecd=mkm_ret_260530_mscpmrk_derm_biologics-in-derm_etid8382686&uac=148436CN&impID=8382686
Identifying Lesions on Skin of Color
Carly A. Elston, MD; Dirk M. Elston, MD
https://reference.medscape.com/p11/identifying-lesions-skin-color-2026a1000eg1?ecd=mkm_ret_260530_mscpmrk_derm_biologics-in-derm_etid8382686&uac=148436CN&impID=8382686
National Psoriasis Foundation Outlines Role of GLP-1 RAs for Psoriasis
Ted Bosworth
https://www.medscape.com/viewarticle/national-psoriasis-foundation-outlines-role-glp-1-ras-2026a1000ear?ecd=mkm_ret_260530_mscpmrk_derm_biologics-in-derm_etid8382686&uac=148436CN&impID=8382686
viernes, 29 de mayo de 2026
Most Read Cancer Science & Oncogenesis +...
https://read.qxmd.com/collection/1133?ecd=wnl_readmost_260529
Triple-negative breast cancer: current understanding and future perspectives.
Triple-negative breast cancer (TNBC) is an aggressive breast cancer subtype defined by the absence of estrogen receptors, progesterone receptors, and human epid..
2026: Exploration of targeted anti-tumor therapy.
Fact vs. Fallacy: Challenging the Norms of Cancer Care Fallacies in Medicine Bishal Gyawali, MD, PhD
https://www.medscape.com/viewarticle/fact-vs-fallacy-challenging-norms-cancer-care-fallacies-2026a1000gei
Hello, everyone. This is Dr Bishal Gyawali, from Queens University, Kingston, Canada. Today, I’m back with you to talk about some of the fallacies that I have seen in medicine, oncology, and the drug regulatory space. I wanted to clarify some of these fallacies.
Which Patients With Early HCC Should Undergo Resection? Daniela Barros l Medscape Europe May 29, 2026
https://www.medscape.com/viewarticle/which-patients-early-hcc-should-undergo-resection-2026a1000hwk
For years, patients with early-stage hepatocellular carcinoma (HCC) who had multiple liver nodules were typically referred for less-invasive locoregional therapies such as radiofrequency ablation (RFA) and transarterial chemoembolization (TACE). The logic seemed sound: to avoid surgical trauma in people who often already have cirrhosis or limited liver function. Now, a new national multicenter meta-analysis suggests that, in carefully selected patients, this approach may need to be reconsidered.
CAR-T Therapy Shows Promise in CNS and Extramedullary B-ALL Edited by Gargi Mukherjee May 29, 2026
https://www.medscape.com/viewarticle/car-t-therapy-shows-promise-cns-and-extramedullary-b-all-2026a1000hyx
CD19 chimeric antigen receptor (CAR) T-cell therapy achieved high response rates in patients with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL) and extramedullary disease or central nervous system (CNS) involvement, according to a retrospective review. More than 80% of patients achieved clearance of their extramedullary or CNS disease; however, patients with concurrent high bone marrow disease burden experienced significantly worse survival than those with low bone marrow burden.
A single viral platform shows promise across infectious disease and cancer ReiThera’s gorilla-derived adenovirus vector is helping advance vaccines and therapies for COVID-19, HIV, Ebola, and even cancer. Written byBree Foster, PhD
A single viral platform shows promise across infectious disease and cancer
ReiThera’s gorilla-derived adenovirus vector is helping advance vaccines and therapies for COVID-19, HIV, Ebola, and even cancer.
Written byBree Foster, PhD
https://www.drugdiscoverynews.com/a-single-viral-platform-shows-promise-across-infectious-disease-and-cancer-17103?utm_campaign=DDN_Newsletter_Dose&utm_medium=email&_hsenc=p2ANqtz-_Tdx3m2iMvdp1D3k42S5hPo1PrPtt3IjBfdsUwgZ-0LEAiv-XA5590T3h9k7W1V0wPFzJZ4rS9-snPUOaMSLUTIou5bg&_hsmi=421171733&utm_content=421171733&utm_source=hs_email
At Advanced Therapies 2026, DDN spoke with Claudio Panzarella, Head of Business Development, and Angelo Raggioli, Head of Technology Development, at ReiThera, about how the company’s early COVID-19 vaccine efforts shaped its current scientific programs, including the gorilla adenovirus (GRAd) platform, ongoing HIV vaccine trials, and the potential for oncology therapeutics.
Ultrasound-triggered nanocatchers turn tumors into personalized vaccines The approach pairs ultrasound-induced tumor cell death with real-time antigen capture to drive both local and systemic immune responses. Written byAndrea Corona
Ultrasound-triggered nanocatchers turn tumors into personalized vaccines
The approach pairs ultrasound-induced tumor cell death with real-time antigen capture to drive both local and systemic immune responses.
Written byAndrea Corona
https://www.drugdiscoverynews.com/ultrasound-triggered-nanocatchers-turn-tumors-into-personalized-vaccines-16921?utm_campaign=DDN_Newsletter_Dose&utm_medium=email&_hsenc=p2ANqtz-8cYDfDkA7hLpNiUtfdXSdBDOWTg0LnoRAnLedX9FV9zUCHeyTuubBA8-NHcn3eg-gjRUFSkVliklr1_12zV6qe7O48bQ&_hsmi=421171733&utm_content=421171733&utm_source=hs_email
A research team in China has developed an ultrasound-responsive nanomaterial that can capture tumor antigens within the tumor microenvironment, addressing one of the central challenges in cancer immunotherapy: how to generate patient-specific immune responses in the face of extreme tumor heterogeneity.
Can one drug repair the brain across multiple CNS diseases? A first-in-class synaptic regenerative approach shows promise across multiple neurodegenerative and neuropsychiatric diseases. Written byBree Foster, PhD
Can one drug repair the brain across multiple CNS diseases?
A first-in-class synaptic regenerative approach shows promise across multiple neurodegenerative and neuropsychiatric diseases.
Written byBree Foster, PhD
https://www.drugdiscoverynews.com/can-one-drug-repair-the-brain-across-multiple-cns-diseases-17191
The human brain contains roughly one hundred billion neurons arranged in extremely intricate networks that generate every thought, memory, emotion, and dream, and coordinate our ability to perceive, respond to, and interact with the world. These remarkable capabilities are only possible if neurons can efficiently coordinate with other cells in the network, using specialized junctions known as synapses.
Weekly Rundown: Oxford scientists develop rapid Ebola vaccine as Congo outbreak grows FDA approvals, pharma deals, and genetic testing advancements led the news this week. Written byDDN editorial team
Weekly Rundown: Oxford scientists develop rapid Ebola vaccine as Congo outbreak grows
FDA approvals, pharma deals, and genetic testing advancements led the news this week.
Written byDDN editorial team
https://www.drugdiscoverynews.com/weekly-rundown-oxford-scientists-develop-rapid-ebola-vaccine-as-congo-outbreak-grows-17195?utm_campaign=DDN_Newsletter_Dose&utm_medium=email&_hsenc=p2ANqtz-9CaSYgo64yBacJHTMjO0uKmroqOegAhmVtlluB9iWyyDXKDHmEvlq9T9XJICNraOUq19CuKzvGGM2JLTybPa_2yKsXAg&_hsmi=421171733&utm_content=421171733&utm_source=hs_email
Scientists at the University of Oxford are developing an experimental Ebola vaccine that could be ready for clinical trials within two to three months, as health authorities race to contain an outbreak in the Democratic Republic of Congo that has caused around 750 suspected cases and 177 deaths. The outbreak, driven by the rare Bundibugyo strain of Ebola has been classified by the World Health Organization as a “very high” risk nationally, with a declared public health emergency of international concern. The Oxford team’s candidate uses the ChAdOx1 viral vector platform, previously deployed in the COVID-19 vaccine developed with AstraZeneca, to deliver genetic material from the Bundibugyo virus via a modified chimpanzee cold virus that cannot cause disease but trains the immune system to recognize the pathogen. While animal studies are now under way and production plans are being prepared with the Serum Institute of India, researchers stress that the vaccine’s effectiveness remains unproven and depends on preclinical and early clinical results. – Bree Foster
New Clinical Trial Testing On-Demand Use of Deucrictibant in Patients With Hereditary Angioedema by Madaline Spencer| Published on: Mar 20, 2026
New Clinical Trial Testing On-Demand Use of Deucrictibant in Patients With Hereditary Angioedema
by Madaline Spencer| Published on: Mar 20, 2026
Peng Lu, MD, PhD, Chief Medical Officer at Pharvaris, and Wim Souverijns, PhD, Chief Commercial Officer at Pharvaris, discuss the RAPIDe-3 clinical trial of deucrictibant for patients with hereditary angioedema (HAE).
https://checkrare.com/new-clinical-trial-testing-on-demand-use-of-deucrictibant-in-patients-with-hereditary-angioedema/
Upcoming Regulatory Decision for LNTH-2501 in the Imaging of Neuroendocrine Tumors by Madaline Spencer| Published on: May 26, 2026
Upcoming Regulatory Decision for LNTH-2501 in the Imaging of Neuroendocrine Tumors
by Madaline Spencer| Published on: May 26, 2026
Mauro Cives, MD, Associate Professor of Medical Oncology at the University of Bari, Italy, discusses the upcoming regulatory decision for LNTH-2501 to improve imaging of neuroendocrine tumors (NETs).
https://checkrare.com/upcoming-regulatory-decision-for-lnth-2501-in-the-imaging-of-neuroendocrine-tumors/
DUET Clinical Trial of Xywav in Patients With Narcolepsy by Madaline Spencer| Published on: May 29, 2026
DUET Clinical Trial of Xywav in Patients With Narcolepsy
by Madaline Spencer| Published on: May 29, 2026
Logan Schneider, MD, Adjunct Clinical Associate Professor of Psychiatry and Behavioral Sciences at Stanford University, discusses the DUET clinical trial of Xywav (low sodium oxybate) in patients with narcolepsy.
https://checkrare.com/duet-clinical-trial-of-xywav-in-patients-with-narcolepsy/
Smarter Step: New Tech Helping Amputees By Ivanhoe Broadcast News on June 5, 2026
Smarter Step: New Tech Helping Amputees
By Ivanhoe Broadcast News on June 5, 2026
RALEIGH, N.C. (Ivanhoe Newswire) — According to the Amputee Coalition, more than two million people in the United States are living with limb loss. And, that number is expected to double by 2050. Losing a leg doesn’t just change how someone walks — it can change how their entire body moves. For many amputees, years of compensating with other muscles can lead to chronic hips, back, and joint pain. Ivanhoe shows us how technology could change lives
https://www.ivanhoe.com/?p=37137&preview=1&_ppp=44d165aa7a
Miles from Maternity Care: AI Helping Expectant Moms By Ivanhoe Broadcast News on June 4, 2026
Miles from Maternity Care: AI Helping Expectant Moms
By Ivanhoe Broadcast News on June 4, 2026
RALEIGH, N.C. (Ivanhoe Newswire) — Across the US, more than 35 percent of counties are now considered a maternity care desert — with no birthing hospital, no birth center, and no obstetric clinician.
https://www.ivanhoe.com/?p=37134&preview=1&_ppp=dd33a2f874
AI’S Impact on Depression By Ivanhoe Broadcast News on June 3, 2026
AI’S Impact on Depression
By Ivanhoe Broadcast News on June 3, 2026
ORLANDO, Fla. (Ivanhoe Newswire) — Artificial Intelligence, or AI for short, has made its way into our everyday lives. Today, more than 65 percent of people use AI on a regular basis. While it can make life easier, some research shows AI may be harmful to your mental health.
https://www.ivanhoe.com/?p=37131&preview=1&_ppp=6df9416ddd
Extreme Cells Hold Key to Pregnancy & Cancer By Ivanhoe Broadcast News on June 2, 2026
Extreme Cells Hold Key to Pregnancy & Cancer
By Ivanhoe Broadcast News on June 2, 2026
RALEIGH, N.C. (Ivanhoe Newswire) — During pregnancy, a mother and baby are connected by a remarkable organ — the placenta. Researchers now say a single massive cell inside that organ may hold clues to pregnancy complications, certain diseases, and even cancer. These so-called “extreme cells” don’t follow the normal rules of biology, and studying them may help scientists better understand how diseases begin.
https://www.ivanhoe.com/?p=37128&preview=1&_ppp=f84fb00356
Arlene’s Fight for 2: Saving Mom & Saving Baby By Ivanhoe Broadcast News on June 1, 2026
Arlene’s Fight for 2: Saving Mom & Saving Baby
By Ivanhoe Broadcast News on June 1, 2026
RALEIGH, NC. (Ivanhoe Newswire) — Breast cancer remains the most common cancer among women in the United States with more than 300 thousand new cases expected this year. About 15 % will be triple-negative — a fast-moving form that does not respond to hormone therapies and often requires aggressive treatment. For some women, there’s another layer of complexity — they’re pregnant. Martie salt introduces us to one mom who faced both battles at once.
https://www.ivanhoe.com/?p=37125&preview=1&_ppp=4115975174
jueves, 28 de mayo de 2026
Safety and efficacy of allogeneic umbilical cord-derived mesenchymal stem cell infusion for frailty: a phase 2, single-centre, randomised, open-label controlled trial Liem T. Nguyena,b,e Send email to liem.nt@vinuni.edu.vn ∙ Kien T. Nguyena,e ∙ Lan T.M. Daoa,e ∙ Van T. Hoanga ∙ Trang T.K. Phana ∙ Nhung T.H. Dinha ∙ et al.
Safety and efficacy of allogeneic umbilical cord-derived mesenchymal stem cell infusion for frailty: a phase 2, single-centre, randomised, open-label controlled trial
Liem T. Nguyena,b,e Send email to liem.nt@vinuni.edu.vn ∙ Kien T. Nguyena,e ∙ Lan T.M. Daoa,e ∙ Van T. Hoanga ∙ Trang T.K. Phana ∙ Nhung T.H. Dinha ∙ et al.
https://www.thelancet.com/journals/ebiom/article/PIIS2352-3964(26)00150-7/fulltext?dgcid=hubspot_update_feature_updatealerts_ebiom&utm_campaign=update-ebiom&utm_medium=email&_hsenc=p2ANqtz--eN-PeSYMQzVYYXXrkjzFcoIRR6Cnnpqq4cP_TpoEPWSf8RfhuoOX-zmM-fDQKPZE7uQ-UGVcQrinK7qjMklwMRQANyg&_hsmi=420912456&utm_content=420560842&utm_source=hs_email
Transcranial temporal interference stimulation targeting the subthalamic region for motor symptoms in Parkinson's disease: a pilot, randomised, double-blind, sham-controlled crossover study Chenhao Yanga ∙ Yongxin Xua ∙ Yichao Dua ∙ Xiaonan Shena ∙ Tingting Lia ∙ Nan Chenb ∙ et al.
Transcranial temporal interference stimulation targeting the subthalamic region for motor symptoms in Parkinson's disease: a pilot, randomised, double-blind, sham-controlled crossover study
Chenhao Yanga ∙ Yongxin Xua ∙ Yichao Dua ∙ Xiaonan Shena ∙ Tingting Lia ∙ Nan Chenb ∙ et al.
https://www.thelancet.com/journals/ebiom/article/PIIS2352-3964(26)00127-1/fulltext?dgcid=hubspot_update_feature_updatealerts_ebiom&utm_campaign=update-ebiom&utm_medium=email&_hsenc=p2ANqtz-90qIaSCtX0-9wJOwZbEDqX_hGQFTuYAsKopdKPQ8fMA6JLUmpCFgpENjQuZWiOShAprfnFOrGbXl-t7PZ8ozZ3lwzyaQ&_hsmi=420912456&utm_content=420560842&utm_source=hs_email
Blood-based biomarker discovery for early pregnancy loss using integrative multi-omics strategies Yue Shia,i ∙ Yongkang Yangb,c,i ∙ Xianghao Guoc ∙ Shuai Shic ∙ Qin Lib,c ∙ Chi Chiu Wanga,d ∙ et al.
Blood-based biomarker discovery for early pregnancy loss using integrative multi-omics strategies
Yue Shia,i ∙ Yongkang Yangb,c,i ∙ Xianghao Guoc ∙ Shuai Shic ∙ Qin Lib,c ∙ Chi Chiu Wanga,d ∙ et al.
https://www.thelancet.com/journals/ebiom/article/PIIS2352-3964(26)00135-0/fulltext?dgcid=hubspot_update_feature_updatealerts_ebiom&utm_campaign=update-ebiom&utm_medium=email&_hsenc=p2ANqtz-93LGpatUDNPkdATM4s8RaZjVEFMZ88kEKWDnHfZyvE3h-8QKE1X99QNJEKw_EF7xmblNT4BpsuKVmAHqQuCqnhtojnJA&_hsmi=420912456&utm_content=420560842&utm_source=hs_email
Editorial Towards biology-informed therapies for long COVID eBioMedicine +...
Editorial
Towards biology-informed therapies for long COVID
eBioMedicine
https://www.thelancet.com/journals/ebiom/issue/vol127nonull/PIIS2352-3964(26)X2003-5
Editorial p393 Shared ownership with young people in health research The Lancet Child & Adolescent Health +... +
Editorial
p393
Shared ownership with young people in health research
The Lancet Child & Adolescent Health
https://www.thelancet.com/journals/lanchi/issue/vol10no6/PIIS2352-4642(26)X2004-1
Safety of in vivo gene therapy in children: mechanisms and management of liver injury
Rebecca Jeyaraj, MRCPCHa,b,c,e Send email to r.jeyaraj@bham.ac.uk ∙ Li-An K Brown, FRCPathd,e ∙ Barath Jagadisan, MDf ∙ Prof Francesco Muntoni, MDe,g ∙ Julien Baruteau, MD PhDc,e,h ∙ Girish Gupte, MDb ∙ et al.
https://www.thelancet.com/journals/lanchi/article/PIIS2352-4642(25)00380-3/abstract?utm_campaign=update-lanchi&utm_medium=email&dgcid=hubspot_update_feature_updatealerts_lanchi&_hsenc=p2ANqtz-9QrxCRagSs_beTr6XJq_XoVjWGW6gSKMSYxR2hLpd1P6j4oUALM441QANXP-ElFBT_hoi88aYoY721gS0UoFamI--fIA&_hsmi=420884426&utm_content=420561182&utm_source=hs_email
Setting priorities for research in addiction Anne Lingford-Hughesa Send email to anne.lingford-hughes@ic.ac.uk ∙ Toto Gronlundb ∙ Eilish Gilvarryc,d on behalf of the James Lind Alliance Priority Setting Partnership for Addiction
Setting priorities for research in addiction
Anne Lingford-Hughesa Send email to anne.lingford-hughes@ic.ac.uk ∙ Toto Gronlundb ∙ Eilish Gilvarryc,d on behalf of the James Lind Alliance Priority Setting Partnership for Addiction
https://www.thelancet.com/journals/lanpsy/article/PIIS2215-0366(26)00023-4/abstract?utm_campaign=update-lanpsy&utm_medium=email&dgcid=hubspot_update_feature_updatealerts_lanpsy&_hsenc=p2ANqtz-8CF8Ml92mDNnLNHY8nuz6FwfLUvUUi24ALE9xMLjq7TaCSjX66o78hTbp8t6-WohKU5h15vvByjU-RJ6hd8bnUyxfYMQ&_hsmi=420895767&utm_content=420561075&utm_source=hs_email
Suscribirse a:
Entradas (Atom)
.png)
